Danish Software Stock News

The Board of Directors of Alm. Brand (CPSE:ALMB) has recommended an ordinary dividend of DKK 0.66 per share for the 2025 financial year, corresponding to a total payout of DKK 0.9b. See our latest analysis for Alm. Brand. At a share price of DKK18.16, Alm. Brand has had a mildly weaker recent patch, with a 1 month share price return of a 3.51% decline, even though its 1 year total shareholder return of 25.93% points to momentum that has built over a longer horizon. If this dividend news has...

What Ringkjøbing Landbobank’s new guidance and buyback could mean for shareholders Ringkjøbing Landbobank (CPSE:RILBA) has set 2026 net profit expectations at DKK 2.0b to DKK 2.4b and backed this outlook with a Board approved share repurchase program of up to DKK 500m. For you as an investor, that combination of earnings guidance and buyback authorization gives two concrete reference points: what management currently expects the business to earn, and how much capital it is prepared to commit...

In recent weeks, Novo Nordisk’s newly launched oral Wegovy weight-loss pill has seen strong early U.S. uptake, with more than 18,000 prescriptions written in its first full week on the market. This rapid adoption highlights physician and patient appetite for a more convenient oral GLP-1 option and may reinforce Novo Nordisk’s competitive positioning in obesity care. We’ll now examine how this rapid uptake of the oral Wegovy pill could influence Novo Nordisk’s broader investment narrative...

With its stock down 12% over the past month, it is easy to disregard Zealand Pharma (CPH:ZEAL). However, a closer look...

Danske Bank has recently updated its outlook, keeping a solid profit forecast for 2025 but signalling lower earnings expectations for 2026 as it rolls out a long-term strategy toward 2030 that is expected to press on shorter-term results. This shift highlights how management is prioritising a multi‑year transformation, accepting near‑term profit pressure to reshape operations and reposition the bank for its 2030 ambitions. We will now examine how Danske Bank’s decision to accept weaker 2026...

Coloplast A/S' ( CPH:COLO B ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right...

A.P. Møller - Mærsk (CPSE:MAERSK B) is structurally returning to its Red Sea Suez Canal route, resuming transits through the corridor despite ongoing regional security concerns. The change affects how Maersk routes a portion of its Asia Europe and related services, shifting some traffic back from longer alternative routes. This decision comes as other global carriers continue to use rerouting options around Africa in response to the same security risks. For you as an investor, this move...

How Genmab’s recent performance frames the story for investors Genmab (CPSE:GMAB) has drawn fresh attention after a period where the stock delivered a 0.6% gain over the past month and 11.5% over the past 3 months, alongside double digit annual revenue and net income growth. See our latest analysis for Genmab. At a share price of DKK2130.0, Genmab’s recent 11.49% 3 month share price return sits alongside a 41.72% 1 year total shareholder return. However, the 3 and 5 year total shareholder...

In January 2026, SSEN Transmission confirmed it has signed final contracts with NKT for two 525 kV HVDC power cable projects in Scotland, adding around €2.00 billion of turnkey design, production and on/offshore installation work to NKT’s high-voltage order backlog. Alongside this, NKT’s launch of the KFEV 245 dry-type outdoor termination highlights how the company is expanding into safer, oil-free high-voltage accessories that address growing environmental and installation concerns in...

The recent installation of the last turbine at Ørsted (CPSE:ORSTED) Greater Changhua 2b and 4 offshore wind farms in Taiwan has sharpened investor focus on how these Asia Pacific projects might influence the stock. See our latest analysis for Ørsted. Ørsted shares have gained momentum recently, with a 30 day share price return of 16.05% and a year to date share price return of 7.62%. This comes even though the 1 year total shareholder return is a 6.86% decline and the 5 year total shareholder...

Netcompany Group's (CPH:NETC) stock is up by a considerable 17% over the past three months. However, we decided to pay...

Readers hoping to buy Per Aarsleff Holding A/S ( CPH:PAAL B ) for its dividend will need to make their move shortly, as...

The board of Alm. Brand A/S ( CPH:ALMB ) has announced that it will be increasing its dividend by 10% on the 14th of...

Novo Nordisk (CPSE:NOVO B) has expanded its partnership with Aspect Biosystems, giving Aspect new rights related to cellular diabetes medicines. Responsibility for certain development and commercialization activities in curative diabetes therapies has shifted within the collaboration. The company has also been named as a defendant in a federal antitrust lawsuit focused on competition in the GLP-1 medication market. Novo Nordisk, known for its diabetes and obesity treatments, is now pushing...

DSV recently broke ground on a new 950,000-square-foot regional headquarters and logistics hub in Mesa, Arizona, a US$14.5 million facility that will integrate air, sea, road, and contract logistics services for the southwestern United States. The site is set to become a central hub serving major clients such as TSMC and Intel, reinforcing DSV’s role in supporting Arizona’s growing semiconductor and technology supply chains. We’ll now look at how this Mesa expansion, particularly its role...

If you are wondering whether Genmab shares still offer value after a strong run, this article walks through what the current price might be implying about the company. The stock is up 5.5% year to date and 40.1% over the last year. However, the 3 year and 5 year returns of 20.1% and 15.0% declines show a more mixed picture. Recent moves in Genmab's share price have come alongside ongoing attention on large biotech names and investor interest in companies with established pipelines, which...

Jyske Bank A/S recently raised its 2025 earnings guidance, now expecting a net profit of DKK 5.40 billion and earnings per share of DKK 85, up from an earlier DKK 4.90–5.30 billion range and DKK 77–84 per share, citing broad business momentum and supportive financial markets. The upgraded outlook, combined with an ongoing share repurchase programme of up to DKK 2.25 billion that has lifted treasury holdings to 5.20% of share capital, highlights management's confidence in the bank's current...

Tryg (CPSE:TRYG) has attracted fresh attention after reporting stronger fourth quarter earnings, announcing a DKK 1b share buyback and lifting its ordinary dividend, with customer satisfaction and Norwegian profitability also moving in a positive direction. See our latest analysis for Tryg. The recent Q4 beat, share buyback launch and higher ordinary dividend come after a year in which the share price has been relatively muted. The 1 year total shareholder return of 15.35% points to momentum...

ISS A/S previously announced a new share buyback programme running from 20 February 2025 to 13 February 2026, with up to DKK 3,000 million earmarked to return excess cash to shareholders and support share-based incentive plans. Following recent transactions, ISS A/S holds 13,393,562 treasury shares, representing 7.69% of its share capital, highlighting the growing role of buybacks in its capital allocation approach. We will now examine how this sizeable DKK 3,000 million buyback shapes ISS...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

If you are wondering whether Novozymes is attractively priced or looking stretched at today’s levels, you are in the right place for a clear, valuation focused rundown of the stock. The share price last closed at DKK 412.0, with returns of 2.6% over the past year and 25.2% over three years. Shorter term moves include a 2.4% decline over 7 days, a 1.8% gain over 30 days, and a 3.8% return year to date. Recent news coverage around Novozymes has largely centered on its role in specialty enzymes...

Ørsted has completed installation of the final wind turbine at its 920 MW Greater Changhua 2b and 4 offshore wind farms in Taiwan, a key milestone for the Asia-Pacific offshore wind industry. The project is the first in the region to supply renewable electricity under a corporate power purchase agreement, with full commercial operations expected in Q3 2026. We will now examine how completing the final turbine installation and progressing toward commercial operations shapes Ørsted’s broader...

Key Insights Per Aarsleff Holding's estimated fair value is kr.860 based on 2 Stage Free Cash Flow to Equity Current...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Demant fair value estimate is kr.302 Current share price of...